Clinical Trial Update: Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion [Phase 1, Phase 2]

View source ↗

Summary

Preliminary safety evaluation update for ART352-L in subjects undergoing posterolateral spinal fusion (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Degenerative Spondylolisthesis

Drugs mentioned

• ART352-L (ART352-L)

Snippet

Sponsor: Ankasa Regenerative Therapeutics, Inc. | Conditions: Degenerative Spondylolisthesis | Phase 1, Phase 2 | Status: UNKNOWN